Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6335 |
Tie2 kinase inhibitor 1
Tie2 kinase inhibitor |
Tie-2 | Tyrosine Kinase/Adaptors |
Tie2 kinase inhibitor 1 (Tie2 kinase inhibitor) 是Tie2激酶选择性抑制剂9IC50:250 nM),具有抗癌作用。 | |||
T36718 |
Tie2 Inhibitor 7
|
||
Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization. | |||
T22259 |
AMG-Tie2-1
AMG-Tie2,4-甲基-3-[[3-[2-(甲基氨基)-4-嘧啶基]-2-吡啶基]氧基]-N-[3-(三氟甲基)苯基]苯甲酰胺 |
Others | Others |
AMG-Tie2-1 is a dual inhibitor of VEGF receptor 2 (VEGFR2) and tunica interna endothelial cell kinase 2 (Tie2). | |||
T8817 |
TIE-2/VEGFR-2 kinase-IN-1
|
||
TIE-2/VEGFR-2 kinase-IN-1 用于合成TIE-2或者VEGFR-2抑制剂,可用于研究不适当的血管生成的相关疾病。 | |||
T40581 |
TIE-2/VEGFR-2 kinase-IN-2
|
||
TIE-2/VEGFR-2 kinase-IN-2 is a powerful inhibitor of both VEGFR2 and Tie-2 kinases, displaying noteworthy pIC 50 values of 8.61 and 8.56, respectively. This compound acts as an anti-angiogenic agent, making it highly relevant for cancer research. | |||
T14921 |
CE-245677
|
Tie-2; Trk receptor | Tyrosine Kinase/Adaptors |
CE-245677 是可逆的Tie2和TrkA/B 抑制剂,在细胞体系下的IC50值分别为 4.7 和 1 nM。 | |||
T6154 |
SU11274
Met Kinase Inhibitor,PKI-SU11274 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; CDK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
SU11274 (Met Kinase Inhibitor) 是一种选择性的 Met 抑制剂,IC50值为 10 nM。它对 PGDFRβ,EGFR 或 Tie2 没有抑制作用。 | |||
T16724 |
Razuprotafib
AKB-9778 |
Phosphatase; Others | Metabolism; Others |
Razuprotafib (AKB-9778) 是一种 VE-PTP (HPTPß)催化活性的有效选择性抑制剂,抑制结构相关磷酸酶 PTP1B。除 HPTPη 和 HPTPγ 外,它对 VE-PTP 具有良好的选择性。它能够促进 TIE2 活化,增强 ANG1 诱导的 TIE2 活化,并刺激 TIE2 通路中信号分子的磷酸化。 | |||
T2640 |
Rebastinib
DCC2036,DCC 2036,DCC-2036 |
Apoptosis; FLT; Bcr-Abl; Src | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Rebastinib (DCC-2036) 是一种口服有效的,非 ATP 竞争性的 Bcr-Abl 抑制剂,作用于 Abl1WT 和 Abl1T315I,IC50分别为 0.8 nM 和 4 nM,还抑制 LYN、SRC、HCK、FGR、FLT3、KDR 和 Tie-2,对 c-Kit 的活性低。Rebastinib 对 Angiopoietin2-Tie2通路具有抑制作用。 | |||
T6380 |
AMG 900
AMG900,AMG-900,莪术醇.姜黄醇 |
p38 MAPK; Tyrosine Kinases; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; Tyrosine Kinase/Adaptors |
AMG 900 是一种有效且高度选择性的泛极光激酶抑制剂,对Aurora A、B 和C 的IC50分别为 5 nM、4 nM 和 1 nM。 | |||
T6479 |
Dovitinib lactate hydrate
Dovitinib (TKI258) Lactate,多韦替尼,Dovitinib Lactate,TKI258 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib lactate hydrate (TKI258) 是一种多靶点的酪氨酸激酶抑制剂,抑制 FLT3,c-Kit,FGFR1/3,VEGFR1/2/3和 PDGFRα/β的 IC50值分别为 1,2,8/9,10/13/8,27/210 nM。 | |||
T6289 |
Dovitinib
TKI258,多韦替尼,CHIR-258,度维替尼 |
VEGFR; FGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib (CHIR-258) 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂,具有抗肿瘤作用。 | |||
T2054 |
Altiratinib
DCC-2701 |
VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂,能够抑制 MET (IC50:2.7 nM),TIE2 (IC50:8 nM),VEGFR2 (IC50:9.2 nM),FLT3 (IC50:9.3 nM),Trk1 (IC50:0.85 nM),Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。 | |||
T79860 |
TIE-2/VEGFR-2 kinase-IN-5
|
VEGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
TIE-2/VEGFR-2 kinase-IN-5 是一种高效的 TIE-2 和 VEGFR-2 酪氨酸激酶受体抑制剂,具有的抗血管生成活性,常用于血管生成相关的生物医学研究领域。 | |||
T38930 |
BAY-826
|
Tie-2 | Tyrosine Kinase/Adaptors |
BAY-826 是一种新型、高效且具有选择性的 TIE-2 抑制剂,抑制 TIE-2 磷酸化,可用于研究肿瘤。 | |||
T6934 |
Pexmetinib
ARRY-614 |
Tie-2; p38 MAPK; Autophagy | Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Pexmetinib (ARRY-614) 是一种口服生物可利用的双重 p38 MAPK/Tie-2 抑制剂,可研究急性骨髓性白血病。在 HEK-293 细胞系中的 IC50 为 4 nM/18 nM。 | |||
T16853 |
SB-633825
|
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 150 nM, respectively). | |||
T4318 |
EOC317
ACTB-1003,ACTB1003,ACTB 1003 |
VEGFR; FGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
EOC317 (ACTB-1003) 是一种口服可用的激酶抑制剂,能够抑制 FGFR1 (IC50:6 nM),VEGFR2 (IC50:2 nM) 和 Tie-2 (IC50:4 nM)。 | |||
T68286 |
CE-245677 mesylate
|
||
CE-245677 is a selective, orally active Tie2 kinase inhibitor identified by Pfizer previously in development for the treatment of certain cancers. CE-245,677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50 of 4.7 and 1 nM, resp., displays >100x selectivity against a number of other angiogenic receptor tyrosine kinases (e.g. KDR, PDGFR, FGFR) and gene family panels, and demonstrates good oral absorption in in vivo rat PK studies (F=80%). | |||
T68539 |
CEP-11981
BOL 303213X,ESK981 ; BOL 303213X,ESK981 |
||
CEP-11981 (ESK981 ; BOL 303213X) 是一种具有口服活性的酪氨酸激酶抑制剂(TKI),可以靶向 TIE2,VEGFR1-3和FGFR1,具有潜在的抗肿瘤和抗血管生成效果。 | |||
T78248 |
Nesvacumab
|
||
Nesvacumab为全人源IgG1型单克隆抗体,具有高亲和力,可特异性结合并灭活Tie2受体配体Angiopoietin-2(Ang2),与Ang1无结合作用。 | |||
T6193 |
Dovitinib Dilactic Acid
Dovitinib (TKI-258) Dilactic Acid,TKI258 Dilactic acid |
VEGFR; FGFR; FLT; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Dovitinib Dilactic Acid (Dovitinib(TKI-258) Dilactic Acid) 是 Dovitinib 的双乳酸,是一种多靶点 RTK 抑制剂,主要用于 III 类 (FLT3/c-Kit),IC50 为 1 nM/2 nM,对 IV 类 (FGFR1/ 3) 和 V 类 (VEGFR1-4) RTK,IC50 为 8-13 nM,对 InsR、EGFR、c-Met、EphA2、Tie2、IGFR1 和 HER2 的效力较低。 | |||
T3113 |
Foretinib
GSK089,EXEL-2880,GSK1363089,XL880 |
VEGFR; Tie-2; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Foretinib (GSK1363089) 是多靶点酪氨酸激酶抑制剂,能够抑制 Met (IC50:0.4 nM) 和 KDR (IC50:0.9 nM)。 | |||
T79858 |
TIE-2/VEGFR-2 kinase-IN-3
|
||
TIE-2/VEGFR-2 kinase-IN-3,为苯并咪唑衍生物,具备高效的抑制作用于TIE-2与VEGFR-2受体酪氨酸激酶,其IC50值分别达到6.9 nM和3.5 nM。本化合物主要用于血管生成相关研究。 | |||
T79859 |
TIE-2/VEGFR-2 kinase-IN-4
|
||
TIE-2/VEGFR-2 kinase-IN-4,一种苯并咪唑衍生物,作为有效的TIE-2和VEGFR-2酪氨酸激酶受体抑制剂,其IC50值分别为5.2 nM和5.1 nM,适用于血管生成相关研究。 |